Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through video calls and online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
A biologic is a medicine that is made in a living system, such as yeast, bacteria, or animal cells. A biosimilar is a medicine that is very close in structure and function to a specific biologic medicine (also known as the reference product). The biosimilar has a structure that is highly similar to, but not exactly the same as, the brand name biologic. A biosimilar behaves in much the same way, so that there are "no meaningful differences" between it and the original biologic. To learn more, see What Are Biosimilar Drugs?
For some brand name biologics used in the treatment of cancer, one or more biosimilars are now approved for use by the US Food and Drug Administration (FDA).
Biosimilars for the biologic medicine bevacizumab (Avastin):
Biosimilars for the biologic medicine rituximab (Rituxan):
Biosimilars for the biologic medicine trastuzumab (Herceptin):
Biosimilars for the biologic medicine filgrastim (Neupogen):
Biosimilars for the biologic medicine pegfilgrastim (Neulasta):
Biosimilar for the biologic medicine epoetin alfa (Epogen):
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
US Food and Drug Administration. Biosimilar Product Information. 2022. Accessed at https://www.fda.gov/drugs/biosimilars/biosimilar-product-information on May 31, 2022.
Last Revised: September 28, 2022